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Abstract	
	
Background:	 Integration	 of	 transcriptomic	 and	 metabolomic	 data	 improves	 functional	
interpretation	of	disease-related	metabolomic	phenotypes,	and	facilitates	discovery	of	putative	
metabolite	biomarkers	and	gene	targets.	For	this	reason,	these	data	are	increasingly	collected	
in	 large	 (>	 100	 participants)	 cohorts,	 thereby	 driving	 a	 need	 for	 the	 development	 of	 user-
friendly	 and	 open-source	 methods/tools	 for	 their	 integration.	 Of	 note,	 clinical/translational	
studies	 typically	 provide	 snapshot	 (e.g.	 one	 time	 point)	 gene	 and	 metabolite	 profiles	 and,	
oftentimes,	 most	 metabolites	 measured	 are	 not	 identified.	 Thus,	 in	 these	 types	 of	 studies,	
pathway/network	 approaches	 that	 take	 into	 account	 the	 complexity	 of	 transcript-metabolite	
relationships	may	 neither	 be	 applicable	 nor	 readily	 uncover	 novel	 relationships.	With	 this	 in	
mind,	we	propose	a	simple	linear	modeling	approach	to	capture	disease-(or	other	phenotype)	
specific	gene-metabolite	associations,	with	 the	assumption	 that	co-regulation	patterns	 reflect	
functionally	related	genes	and	metabolites.		
	
Results:	 The	 proposed	 linear	 model,	 metabolite	 ~	 gene	 +	 phenotype	 +	 gene:phenotype,		
specifically	 evaluates	 whether	 gene-metabolite	 relationships	 differ	 by	 phenotype,	 by	 testing	
whether	 the	 relationship	 in	 one	 phenotype	 is	 significantly	 different	 from	 the	 relationship	 in	
another	phenotype	(via	a	statistical	interaction	gene:phenotype	p-value).	Statistical	interaction	
p-values	 for	 all	 possible	 gene-metabolite	 pairs	 are	 computed	 and	 significant	 pairs	 are	 then	
clustered	 by	 the	 directionality	 of	 associations	 (e.g.	 strong	 positive	 association	 in	 one	
phenotype,	strong	negative	association	in	another	phenotype).	We	implemented	our	approach	
as	an	R	package,	IntLIM,	which	includes	a	user-friendly	R	Shiny	web	interface,	thereby	making	
the	 integrative	 analyses	 accessible	 to	 non-computational	 experts.	We	 applied	 IntLIM	 to	 two	
previously	 published	 datasets,	 collected	 in	 the	 NCI-60	 cancer	 cell	 lines	 and	 in	 human	 breast	
tumor	and	non-tumor	tissue,	for	which	transcriptomic	and	metabolomic	data	are	available.	We	
demonstrate	 that	 IntLIM	 captures	 relevant	 tumor-specific	 gene-metabolite	 associations	
involved	in	known	cancer-related	pathways,	including	glutamine	metabolism.	Using	IntLIM,	we	
also	 uncover	 biologically	 relevant	 novel	 relationships	 that	 could	 be	 further	 tested	
experimentally.			
	
Conclusions:	 IntLIM	 provides	 a	 user-friendly,	 reproducible	 framework	 to	 integrate	
transcriptomic	and	metabolomic	data	and	help	interpret	metabolomic	data	and	uncover	novel	
gene-metabolite	 relationships.	 The	 IntLIM	 R	 package	 is	 publicly	 available	 in	 GitHub	
(https://github.com/mathelab/IntLIM)	and	 includes	a	user-friendly	web	application,	vignettes,	
sample	data	and	data/code	to	reproduce	results.			
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Background	
	
Metabolomics	data	is	increasingly	collected	in	human	biospecimens	to	identify	putative	
biomarkers	in	diseases	such	as	cancer	[1-6].	Metabolites	(small	molecules	<	1500	Daltons)	are	
ideal	candidates	 for	biomarker	discovery	because	they	directly	 reflect	disease	phenotype	and	
downstream	 effects	 of	 post-translational	 modifications	 [6].	 However,	 interpretation	 of	
metabolomics	 data,	 including	 understanding	 how	 metabolite	 levels	 are	 modulated,	 is	
challenging.	Reasons	for	this	challenge	include	the	presence	of	many	(hundreds)	of	unidentified	
metabolites	when	untargeted	 approaches	 are	 applied	 [7,	 8],	 and	 the	 fact	 that	metabolomics	
profiles	 generated	 in	 human	 biospecimens	 are	 typically	 ‘snapshots’	 or	 time-averaged	
representations	 of	 a	 disease	 state.	 Despite	 these	 difficulties,	 analyzing	metabolomics	 data	 in	
light	of	other	omics	 information,	such	as	the	transcriptome,	can	help	to	functionally	 interpret	
metabolomics	 phenotypes	 [9-15].	 	 Data	 integration,	 or	 the	 use	 of	 multiple	 sources	 of	
information	or	data	to	provide	a	better	model	and	understand	a	biological	system	[16],	offers	
the	opportunity	to	combine	metabolomics	data	with	other	omics	data-sets	(e.g.	transcriptome).		
Measurement	 and	 integration	 of	 the	 transcriptome	 and	 metabolome	 in	 the	 same	 cells,	
samples,	 or	 individuals,	 are	 thus	 increasingly	 applied	 to	 elucidate	 mechanisms	 that	 drive	
diseases,	and	to	uncover	putative	biomarkers	(metabolites)	and	targets	(genes).	
	
Current	approaches	that	integrate	transcriptomic	and	metabolomic	data	can	be	broadly	
categorized	 as	 numerical	 or	 pathway/network	 based.	 	 Numerical	 approaches	 include	
multivariate	 analyses	 (e.g.	 logistic	 regression,	 principal	 component	 analysis,	 partial	 least	
squares)	 and	 correlation-based	 approaches	 (e.g.	 canonical	 correlations)	 [17-19].	 Differential	
correlation	 or	 coexpression	 methods	 have	 also	 been	 developed	 to	 capture	 changes	 in	
relationships	 between	 conditions	 [20].	 Open-source	 tools,	 including	 MixOmics	 [21,	 22]	 and	
DiffCorr	 [23],	 are	 available	 for	 integrating	 data	 but	 generally	 require	 in-depth	 statistical	
knowledge	for	their	use	and	may	not	be	as	accessible	to	non-computational	experts.	Of	note,	
such	 numerical	 approaches	 typically	 do	 not	 capture	 the	 complex	 and	 indirect	 relationships	
between	 transcripts	 and	metabolites.	 For	 example,	 non-linear	 reaction	 kinetics	mechanisms,	
metabolite-metabolite	 connections	 that	 regulate	 metabolite	 levels,	 and	 post-translational	
modifications	 all	 contribute	 to	 the	 complexity	 of	 gene-metabolite	 relationships	 [24,	 25].	 To	
better	 capture	 these	 complex	 relationships,	 pathway	 or	 network	 based	 approaches	 can	 be	
applied.	 	 Open-source	 tools	 such	 as	 Metaboanalyst	 [26],	 INMEX	 [27],	 XCMS	 Online	 [28],	
Metabox	[29],	and	IMPALA	[30]	integrate	transcriptomic	and	metabolomics	data	at	a	pathway	
level.	 	One	caveat	of	these	approaches	is	that	they	rely	on	curated	pathways	or	reaction-level	
information	 (knowledge	 of	 which	 enzymes	 produce	 a	 given	 metabolite)	 [18].	 Pathway	
approaches	 are	 thus	 limited	 to	 metabolites	 that	 are	 identified	 and	 that	 can	 be	 mapped	 to	
pathways,	 which	 represents	 a	 fraction	 of	 what	 can	 be	 measured.	 	 In	 fact,	 of	 the	 114,100	
metabolites	 in	 the	 Human	 Metabolome	 Database	 [31-33],	 only	 18,558	 are	 detected	 and	
quantified,	 and	 of	 those,	 only	 3,115	 (17%)	 map	 to	 KEGG	 pathways.	 	 Further,	 network	
approaches	that	attempt	to	study	the	complex	many	to	many	associations	between	genes	and	
metabolites	may	not	scale	well	when	tens	of	thousands	of	gene-metabolite	pairs	are	evaluated.			
	
Importantly,	 previous	 studies	 have	 shown	 that	 functionally	 related	 genes	 and	
metabolites	 show	 coherent	 co-regulation	 patterns	 [20,	 34,	 35].	 	 We	 make	 this	 functionality	
assumption	 here	 and	 propose	 a	 linear	modeling	 approach	 for	 integrating	metabolomics	 and	
transcriptomics	 data	 to	 identify	 phenotype-specific	 gene-metabolite	 relationships.	 Of	 note,	
typical	 numerical	 integration	 approaches	 uncover	 patterns	 of	 molecular	 features	 that	 are	
globally	correlated	or	aim	to	predict	phenotype	[20].		However,	these	methods	do	not	directly	
and	statistically	test	whether	associations	between	metabolites	and	gene	expression	differ	by	
phenotype.	 This	 distinction	 is	 important	 because	 global	 associations	 between	 genes	 and	
metabolites	may	not	 only	 reflect	 one	phenotype	of	 interest,	 but	 could	 reflect	 other	 features	
(e.g.,	 environment,	 histology).	 As	 for	 methods	 that	 uncover	 differentially	 correlated	 pairs	
between	conditions	[35],	they	either	do	not	capture	pairs	of	features	that	are	correlated	in	one	
group	and	not	correlated	 in	another	group,	or	they	bin	relationships	 into	different	types	(e.g.	
positive	 correlation	 in	 one	 group,	 negative	 correlation	 in	 another	 group),	 thereby	 making	 it	
difficult	 to	compare	more	 than	2	phenotypes	 [20,	34,	35].	 Further,	 these	approaches	are	not	
implemented	 into	 user-friendly	 frameworks.	 Our	 approach	 is	 thus	 advantageous	 because	 it	
directly	evaluates	the	relationship	between	genes	and	metabolites	in	the	context	of	phenotype,	
it	can	easily	 incorporate	potential	covariates,	and	 is	applicable	to	categorical	 (>=	2	groups)	or	
continuous	phenotypes.	Further,	our	approach	is	implemented	as	a	publicly	available	R	package	
IntLIM	 (Integration	 through	 Linear	Modeling),	 available	 at	 our	 GitHub	 repository	 [36],	 which	
includes	an	R	Shiny	web	interface	making	it	user-friendly	to	non-computational	experts.	In	the	
wake	of	increasing	amounts	of	metabolomics	and	transcriptomic	data	generated,	availability	of	
open-source,	user-friendly,	and	streamlined	approaches	is	key	for	reproducibility.	Using	IntLIM,	
we	evaluated	phenotype-specific	relationships	between	gene	and	metabolite	 levels	measured	
in	 the	 NCI-60	 cancer	 cell	 lines	 [10],	 and	 in	 tumor	 and	 adjacent	 non-tumor	 tissue	 of	 breast	
cancer	 patients	 [9].	 We	 demonstrate	 that	 IntLIM	 is	 useful	 for	 uncovering	 known	 and	 novel	
gene-metabolite	relationships	(which	would	require	further	experimental	validation).		
	
Methods	
	
NCI-60	Cell	Line	Data	Pre-processing		
The	 NCI-60	 cancer	 cell	 line	metabolomics	 (Metabolon	 platform)	 and	 gene	 expression	
data	 (Affymetrix	 U133	 microarray)	 were	 downloaded	 from	 the	 Developmental	 Therapeutics	
Program	(National	Cancer	Institute)	website	[10,	37].		Metabolomics	and	gene	expression	data,	
available	in	57	cell	 lines,	were	pre-processed	and	normalized	according	to	the	Metabolon	and	
Affymetrix	 MAS5	 algorithms	 [38,	 39],	 respectively.	 The	 metabolomics	 data	 contains	 353	
metabolites,	of	which	198	are	unidentified.	Each	cell	 line	 is	measured	 in	 triplicates	 (technical	
replicates),	 except	 for	 A498	 and	 A549/ATCC,	 which	 had	 4	 and	 2	 technical	 replicates,	
respectively.	 The	median	 of	 coefficients	 of	 variation	 (CVs)	within	 technical	 replicate	 samples	
was	 calculated	 for	 each	 metabolite	 to	 assess	 consistency	 of	 abundance	 measurements.	
Metabolites	with	CVs	<	0.3	were	removed	(280	metabolites	remaining),	abundances	were	log2	
transformed,	 and	 the	 average	 technical	 replicate	 value	 was	 calculated	 for	 each	 metabolite.	
Next,	 the	 number	 of	 imputed	 values	 was	 estimated	 for	 each	 metabolite.	 The	 standard	
imputation	method	used	by	Metabolon	 is	 to	 impute	missing	values	 for	a	given	metabolite	by	
the	 minimum	 value	 of	 that	 metabolite	 across	 all	 samples.	 	 Thus,	 for	 each	 metabolite,	 the	
number	 of	 samples	with	 a	 value	 equal	 to	 the	minimum	 value	 (for	 that	metabolite	 across	 all	
samples)	minus	“1”	(one	of	those	values	is	the	true	minimum	value	and	should	be	subtracted)	
was	 used	 as	 an	 estimate	 of	 the	 number	 of	missing	 values	 per	metabolite.	 	Metabolites	with	
more	than	80%	imputed	values	were	filtered	out	resulting	in	220	metabolites,	111	of	which	are	
unidentified.	Probes	from	the	Chiron	Affymetrix	U133	microarrays	were	mapped	to	genes	using	
the	Bioconductor	Ensembl	database	hgu133.plus.db	[40].	In	cases	where	more	than	one	probe	
was	matched	to	a	given	gene,	the	probe	with	the	highest	mean	expression	across	all	samples	
was	 retained	 for	 analysis,	 resulting	 in	 17,987	 genes	 with	 available	 expression.	 Lastly,	 we	
removed	the	10%	(arbitrary	cutoff)	of	the	lowest	expressing	genes,	resulting	in	a	total	of	16,188	
genes.	For	the	linear	modeling	analyses,	220	metabolites	and	16,188	genes	were	input.	
	
For	 the	 NCI-60	 cell	 line	 data,	 the	 phenotypes	 compared	 were	 leukemia	 cell	 lines	 vs.	
breast/prostate/ovarian	 (BPO)	 cell	 lines.	 	 Because	 this	 dataset	 was	 used	 to	 develop	 our	
approach,	we	purposefully	 chose	 cells	 from	 cancers	 that	 are	 known	 to	 be	 highly	 different	 in	
terms	of	their	molecular	profiles	(e.g.	blood	cancer	vs.	solid	tumor).		The	breast,	prostate,	and	
ovarian	cancer	cell	lines	were	grouped	together	because	they	share	susceptibility	loci	[41]	and	
our	aim	was	to	increase	sample	size.		
	
Breast	Cancer	Data	Pre-Processing		
Normalized	 gene	 expression	 (Affymetrix	 Gene	 Chip	 Human	 Gene	 1.0	 ST	 Arrays)	 and	
metabolomics	 (Metabolon)	 data	 in	 tumor	 and	 adjacent	 non-tumor	 tissue	 of	 breast	 cancer	
patients	 are	 publicly	 available	 through	 the	 Gene	 Expression	 Omnibus	 (GSE37751)	 and	 the	
supplementary	data	of	 the	original	publication,	 respectively	 [9,	42].	The	data	was	normalized	
using	 the	Metabolon	 algorithm	 (metabolites)	 and	 RMA	 algorithm	 [43]	 (genes),	 as	 previously	
described	[9].		Both	gene	and	metabolite	levels	are	available	for	61	tumor	and	47	adjacent	non-
tumor	 breast	 tissue.	 	 The	metabolomics	 data	 consists	 of	 536	metabolites	 (203	 of	 which	 are	
unidentified)	in	tumor	and	non-tumor	tissue.	Metabolites	with	more	than	80%	imputed	values	
were	 removed,	 resulting	 in	 379	metabolites,	 119	 of	which	 are	 unidentified.	 Probes	 from	 the	
gene	 expression	 data	 not	 mapping	 to	 a	 gene	 symbol	 (Human	 Gene	 1.0	 ST	 Arrays)	 were	
removed.	 	 Similar	 to	 the	 NCI-60	 data	 pre-processing,	 the	 probe	 with	 the	 highest	 mean	
expression	was	used	for	analysis	when	multiple	probes	mapped	to	a	single	gene.	This	resulted	
in	 20,254	 genes	 measured	 in	 tumor	 and	 non-tumor	 tissue.	 After	 removing	 the	 10%	 lowest	
expression	 genes,	 we	 analyzed	 18,228	 genes.	With	 this	 breast	 cancer	 data,	 our	 aim	 was	 to	
compare	 gene-metabolite	 associations	 between	 tumor	 and	 non-tumor	 tissue.	 A	 total	 of	 379	
metabolites	and	18,228	genes	were	used	for	this	analysis.	
	
IntLIM:		Integration	through	Linear	Modeling	Approach		
The	linear	model	applied	to	integrate	transcriptomic	and	metabolomic	data	is:			
	
	 	 (1)	
	
where	 “m”	 and	 “g”	 are	 normalized	 (see	 data	 pre-processing	 above)	 and	 log2-transformed	
metabolite	abundances	and	gene	levels	respectively,	“p”	is	phenotype	(e.g.	cancer	type,	tumor	
vs.	normal),	“(g:p)”	 is	the	statistical	interaction	[44]	between	gene	expression	and	phenotype,	
and	“ε”	is	the	error	term	that	is	assumed	to	be	independent	and	normally	distributed	(ε	=	N(0,	
σ	)).	 	A	statistically	significant	two-tailed	p-value	of	the	“(g:p)”	 interaction	term	indicates	that	
the	slope	relating	gene	expression	and	metabolite	abundance	is	different	from	one	phenotype	
compared	to	the	other.		Through	this	model,	we	can	identify	gene-metabolite	associations	that	
are	specific	 to	a	particular	phenotype	 (Figure	1).	 	This	model	has	been	applied	 to	all	possible	
gene-metabolite	 pairs	 including	 those	 involving	 unidentified	 metabolites	 in	 the	 publicly	
available	NCI-60	 cancer	 cell	 line	data	 [10]	 as	well	 as	previously	published	data	 from	a	breast	
cancer	 study	 [9].	 	 Two-tailed	 p-values	 are	 subsequently	 corrected	 for	 multiple	 comparisons	
using	 the	method	 by	 Benjamini	 and	Hochberg	 to	 control	 the	 false	 discovery	 rate	 (FDR)	 [45].		
Gene-metabolite	pairs	with	an	FDR-adjusted	 interaction	p-value	 less	 than	0.10	or	0.05	 in	 the	
NCI-60	 cell	 line	 and	 breast	 cancer	 data,	 respectively,	 were	 used	 to	 determine	 statistical	
significance.		(Due	to	the	larger	sample	size	in	the	breast	cancer	data	set	and	the	much	larger	
amount	of	significant	gene-metabolite	pairs,	our	threshold	for	significance	was	more	stringent).	
	
Figure 1. IntLIM defines phenotype-specific gene-metabolite pairs by uncovering gene-metabolite pairs that show an 
association in one phenotype (e.g. tumors) and another or no association in another phenotype (e.g. non-tumors).  
 
To	 filter	 and	 cluster	 the	 list	 of	 statistically	 significant	 gene-metabolite	 pairs,	 the	
difference	 in	 Spearman	 correlations	 between	 the	 two	 phenotypic	 groups	 being	 compared	
(leukemia	vs.	BPO	for	NCI-60	cells	and	tumor	vs.	non-tumor	for	breast	cancer	tissue)	was	used	
as	an	effect	size.		Volcano	plots	of	the	difference	in	Spearman	correlations	vs.	the	–log10	(FDR-
adjusted	p-values)	are	depicted	to	visualize	the	distributions	and	help	determine	appropriate	p-
value	and	effect	size	cutoffs	(Figure	S3).		For	both	datasets,	a	minimum	absolute	difference	in	
correlations	of	0.5	was	used	as	an	effect	size	cutoff.	
	
The	results	can	be	visualized	via	a	hierarchically	clustered	heatmap	of	gene-metabolite	
Spearman	 correlations	 calculated	 for	 each	 phenotypic	 group.	 	 Hierarchical	 clustering	 is	
performed	with	the	hclust	function.		The	Euclidean	distance	is	used	as	the	distance	metric	and	
the	complete	linkage	method	is	used	for	agglomeration.	 	The	resulting	dendrogram	is	used	to	
create	a	heatmap	that	helps	visualize	how	relevant	gene-metabolite	pairs	cluster	by	their	effect	
size	(e.g.	differences	in	Spearman	correlation	between	the	two	phenotypic	groups).				
	
IntLIM	R	Package		
A	pipeline	has	been	developed	in	the	form	of	an	R	package	to	streamline	integration	of	
metabolomics	and	gene	expression	data	using	IntLIM.	The	package	has	been	optimized	and	can	
solve	a	high	number	of	linear	models	(3-7	million	gene-metabolite	pairs)	in	2	to	6	minutes	on	a	
laptop	with	2.7GHz	quad-core	Intel	Core	i7	processor	and	16	GB,	2133MHz	memory.		Of	note,	
IntLIM	 requires	 less	 than	 3%	 of	 the	 time	 to	 solve	 all	 possible	 linear	 models	 compared	 to	
iterating	 through	 each	 model	 using	 the	 lm	 function	 in	 R	 for	 performing	 linear	 regression	
analysis	 as	 it	 contains	 a	 matrix	 algebra	 implementation	 of	 that	 function	 [46].	 	 Extensive	
documentation	 is	 available	 in	 the	 package,	 including	 a	 vignette,	 and	 formatted	 NCI-60	 and	
breast	cancer	datasets	are	linked	and	available	in	the	IntLIM	GitHub	repository	[36].		The	steps	
for	analysis	are:		
	
1)	Load	data:	input	CSV	files	containing	normalized	and	log2-transformed	gene	expression	data,	
normalized	and	 log2-transformed	metabolite	abundance	data,	metadata	for	the	samples	 (e.g.	
cancer	status),	and	optionally	metadata	information	on	the	genes	and	metabolites		
	
2)	 Filter	 data:	 gene	 expression	 and	 metabolomics	 data	 are	 optionally	 filtered	 by	 gene	 and	
metabolite	abundances	and	missing	values	
	
3)	 Run	 IntLIM:	 	 run	 linear	 models	 for	 all	 possible	 gene-metabolite	 pairs	 and	 extract	 FDR-
adjusted	 interaction	 p-values	 and	 effect	 sizes	 (e.g.	 differences	 in	 slope/correlations	 between	
the	groups)	
	
4)	Filter	gene-metabolite	pairs:	filter	results	by	user-input	cutoffs	of	FDR-adjusted	p-values	and	
effect	size.		A	volcano	plot	(absolute	difference	in	correlation	vs.	–log10(FDR-adjusted	p-values)	
is	 shown	 to	 help	 users	 determine	 appropriate	 adjusted	 p-value	 and	 effect	 size	 cutoffs.		
Resulting	 pairs	 are	 then	 clustered	 with	 hierarchical	 clustering,	 based	 on	 correlations	 within	
each,	and	visualized	through	heatmaps.	
	
5)	 Visualize	 relevant	 gene-metabolite	 pairs:	 user-selected	 gene-metabolite	 pairs	 can	 be	
visualized	through	scatterplots,	color-coded	by	phenotypic	groups	of	interest	(e.g.	leukemia	vs.	
BPO,	tumor	vs.	non-tumor).	
	
The	 IntLIM	 package	 also	 includes	 an	 RShiny	 web	 interface,	 a	 powerful	 tool	 that	
transforms	complex	analysis	pipelines	into	interactive,	user-friendly	web	applications	[47].	The	
App	guides	users	through	all	steps	available	in	the	package,	as	mentioned	above.		Of	note,	most	
plots	are	coded	in	highcharter	[48]	or	plotly	[49,	50]	so	users	can	promptly	assess	the	effect	of	
changing	parameters	on	analysis	 results	 (e.g.	 immediate	updates	of	 tables	and	plots	resulting	
from	user	changes	of	effect	size	and	p-value	cutoffs).	We	believe	this	 interactivity	accelerates	
data	analysis	and	hence	discovery	of	phenotype-specific	gene-metabolite	pairs.	Further	the	app	
makes	 the	 analysis	 accessible	 to	 non-computational	 researchers.	 More	 information	 can	 be	
found	in	the	S1	Appendix:	IntLIM	documentation.	
	
Pathway	Analysis		
Pathway	and	upstream	regulator	analyses	were	performed	using	the	Ingenuity	Pathway	
Analysis	(IPA)	software.	The	list	of	genes	or	identified	metabolites	from	each	cluster	(e.g.	highly	
correlated	 in	 one	 group	 but	 no	 correlation	 in	 the	 other)	 of	 statistically	 significant	 gene-
metabolite	pairs	were	input	to	conduct	pathway	analysis	to	analyze	input	genes	or	metabolites	
in	the	context	of	biological	pathways	or	functions	[51].	IPA	also	includes	an	upstream	regulator	
analysis	 to	 determine	 whether	 those	 molecules	 were	 associated	 with	 a	 particular	 upstream	
regulator.	 	 P-values,	 calculated	 from	 the	 Right-tailed	 Fisher’s	 Exact	 Test,	 reflect	whether	 the	
number	of	overlapping	molecules	associated	with	a	particular	pathway	or	upstream	regulator	is	
greater	than	expected	by	chance	[52].	For	upstream	regulator	analysis,	both	direct	and	indirect	
relationships	 between	 molecules	 and	 their	 targets	 were	 considered	 (confidence	 =	
Experimentally	observed).	[53].			
	
Results	
	
IntLIM	(Integration	through	LInear	Modeling)	
	
Our	 goal	 is	 to	 find	 gene-metabolite	 pairs	 that	 have	 a	 strong	 association	 in	 one	
phenotype	(e.g.	leukemia	vs.	breast/prostate/ovarian	cancers	(BPO),	tumor	vs.	non-tumor)	and	
an	 inverse	 or	 no	 association	 in	 another	 phenotype.	 We	 anticipate	 that	 gene-metabolite	
relationships	that	are	phenotype	dependent	will	help	interpret	metabolomics	phenotypes	and	
will	 highlight	molecular	 functions	 and	pathways	worth	 evaluating	 further.	With	 accumulating	
transcriptomic	and	metabolomics	data	generated	in	the	same	samples,	uncovering	phenotype-
specific	 relationships	 could	 elucidate	 novel	 co-regulation	 patterns.	 Because	 commonly	
leveraged	 untargeted	 metabolomics	 approaches	 produce	 large	 amounts	 of	 unidentified	
metabolites,	 approaches	 that	 rely	 on	 reaction-level	 or	 pathway	 annotations	 may	 not	 be	
sufficient	 to	 capture	 all	 or	 novel	 relationships.	 To	 accomplish	 our	 goal,	 we	 thus	 rely	 on	
numerical	data	integration	and	developed	a	linear	modeling	approach	that	predicts	metabolite	
levels	 from	 gene	 expression	 in	 a	 phenotype-dependent	 manner	 (Figure	 1)	 (see	 Methods).		
Unlike	correlation-based	and	logistic	regression	approaches,	our	approach	specifically	evaluates	
whether	 the	 association	 between	 gene	 and	 metabolite	 levels	 is	 related	 to	 a	 phenotype.	
Furthermore,	it	is	important	to	keep	in	mind	that	metabolite	abundances	can	be	modulated	by	
a	 group	 of	 enzymes,	 which	 in	 turn	 are	 regulated	 by	 a	 myriad	 of	 regulatory	 processes	 (e.g.	
transcription,	 post-translational	 modifications).	 Thus,	 gene	 expression,	 protein	 abundances,	
and	 metabolite	 levels	 do	 not	 always	 have	 linear	 relationships.	 While	 these	 more	 complex	
relationships	 will	 not	 be	 readily	 detected	 using	 our	 approach	 [14],	 co-regulated	 gene-
metabolite	relationships	tend	to	share	biological	 functions	 [34]	and	we	make	this	assumption	
here.		Our	approach	is	implemented	as	an	R	package,	which	is	publicly	available	through	GitHub	
(See	Methods	and	IntLIM	Documentation	in	S1	Appendix)	[36].					
	
Application	to	NCI-60	Data		
The	NCI-60	cell	 lines	[10]	were	developed	as	a	drug-screening	tool	focusing	on	a	range	
of	cancer	types,	 including	renal,	colon,	prostate,	breast,	ovarian,	 leukemia,	and	non-small	cell	
lung	cancer	[54].	Transcriptomic	(Affymetrix)	and	metabolomic	(Metabolon)	data	are	available	
for	57	of	those	cell	lines	[10]	We	applied	IntLIM	to	identify	cancer-type	specific	gene-metabolite	
associations.		The	two	major	subgroups	compared	were	leukemia	(6	cell	lines:	CCRF-CEM,	HL-60	
(TB),	K-562,	MOLT-4,	RPMI-8226,	SR)	vs.	the	breast/prostate/ovarian	(BPO)	cancer	cell	lines	(14	
total	 cell	 lines:	 	 BT-549,	DU-145,	HS	578T,	 IGROV1,	MCF7,	MDA-MB-231/ATCC,	NCI/ADR-RES,	
OVCAR-3,	OVCAR-4,	OVCAR-5,	OVCAR-8,	PC-3,	SK-OV-3,	T-47D)	consisting	of	16,188	genes	and	
220	 metabolites	 (see	 Methods).	 	 The	 latter	 cancers	 were	 grouped	 together	 as	 they	 share	
common	susceptibility	 loci	 [41].	 	Unsupervised	clustering	using	principal	 components	analysis	
(PCA)	 on	 the	 log2-transformed	 and	 filtered	metabolomics	 and	 gene	 expression	 data	 (Figures	
S1A	and	B)	clearly	delineates	the	two	major	subgroups	(Figure	S1C	and	D).	
	
All	 possible	 combinations	 of	 gene-metabolite	 pairs	 (3,561,360	 models	 run)	 were	
evaluated,	 using	 “BPO”	 and	 “leukemia”	 as	 cancer	 type.	 We	 identified	 1,009	 cancer-type	
dependent	gene-metabolite	associations	(FDR-adjusted	p-value	<	0.1	and	correlation	difference	
effect	size	>	0.5,	Data	S1,	Figure	S3A)	involving	785	genes	and	68	metabolites,	of	which	37	are	
unidentified.	Clustering	of	these	pairs	by	the	direction	of	association	(e.g.	positive	or	negative	
correlation)	within	each	cancer	type	subgroup	revealed	two	major	clusters	(Figure	3).	First,	the	
“leukemia	correlated	cluster”	consists	of	545	gene-metabolite	pairs	(429	unique	genes	and	54	
unique	metabolites	 of	which	 31	 are	 unidentified)	with	 relatively	 high	 positive	 correlations	 in	
leukemia	cell	 lines	and	 low	or	negative	correlations	 in	BPO	cell	 lines	(Figure	2A).	 	Second,	the	
“leukemia	anti-correlated	cluster”	consists	of	464	gene-metabolite	pairs	(356	unique	genes	and	
45	unique	metabolites	of	which	24	are	unidentified)	with	relatively	high	negative	correlations	in	
leukemia	cell	 lines	and	positive	or	 low	negative	correlations	 in	BPO	cell	 lines.	 	Two	of	the	top	
ranked	 gene-metabolite	 pairs	 (ranked	 in	 descending	 order	 of	 absolute	 value	 of	 Spearman	
correlation	differences	between	BPO	and	 leukemia)	 in	 the	 leukemia	 correlated	and	 leukemia	
anti-correlated	 clusters	 are	 FSCN1-malic	 acid	 (Figure	 2B)	 and	 DLG4-leucine	 (Figure	 2C),	
respectively.		FSCN1	and	malic	acid	(Figure	2B)	are	positively	correlated	in	leukemia	(r=0.94)	but	
negatively	 correlated	 in	 BPO	 cancers	 (r	 =	 -0.75)	 (Figure	 2B).	 FSCN1	 is	 associated	 with	 the	
progression	 of	 prostate	 cancer	 [55],	 while	 malic	 acid	 (or	 ionized	 malate)	 is	 an	 intermediate	
involved	in	glutamine	metabolism	pathways	that	play	major	roles	in	cancer	metastasis	[56,	57].		
DLG4	 and	 leucine	 (Figure	 2C)	 are	 negatively	 correlated	 in	 leukemia	 (r	 =	 -0.92)	 but	 positively	
correlated	 (r	 =	 0.78)	 in	 BPO	 cancers	 (Figure	 2C).	 DLG4	 is	 downregulated	 in	 human	 cervical	
cancer	cell	 lines	 infected	with	human	papillomavirus	and	may	act	as	a	tumor	suppressor	[58],	
while	leucine	deprivation	inhibits	cell	proliferation	and	induces	apoptosis	in	breast	cancer	cells	
[59].	 	 Interestingly,	 leucine	 supplementation	 has	 been	 shown	 to	 enhance	 pancreatic	 cancer	
growth	 in	mouse	models	 [60].	 	These	opposing	correlations	of	DLG4-leucine	and	FSCN1-malic	
acid	 between	 leukemia	 and	 BPO	 suggest	 possible	 tissue-specific	 relationships	 that	 can	 be	
differentially	targeted.				
	
Pathway	 analysis	 on	 419	 unique	 and	 mappable	 genes	 in	 the	 “leukemia	 correlated	
cluster”	 showed	enrichment	of	 the	 following	pathways:	 	 acute	phase	 response	 signaling,	 1D-
myo-inositol	 hexakisphosphate	 biosynthesis,	 hepatic	 fibrosis/hepatic	 stellate	 cell	 activation,	
CDK5	 signaling,	 and	 PAK	 signaling	 (Table	 S1).	 The	 “leukemia	 anti-correlated	 cluster”	 genes	
(N=351)	were	enriched	for	endothelial	NOS	signaling,	CREB	signaling	in	neurons,	dTMP	de	novo	
biosynthesis,	Huntington’s	Disease	signaling,	and	the	P2Y	purigenic	receptor	signaling	pathway	
(Table	S1).	 	Most	of	these	pathways	are	relevant	to	cancer	biology.	 	For	example,	nitric	oxide	
has	been	found	to	have	both	tumor	suppressive	(e.g.	promoting	apoptosis,	inhibition	of	cancer	
Figure 2. Results of IntLIM applied to NCI-60 data.  A) Clustering of Spearman correlations of 1,009 identified gene-metabolite 
pairs(16,188 genes and 220 metabolites, 57 cell lines) (FDR adjusted p-value of interaction coefficient < 0.10 with Spearman 
correlation difference of > 0.5) in “BPO” and leukemia NCI-60 cell lines.  Examples of two gene-metabolite associations with 
significant differences:  B) FSCN1 and malic acid (FDR adj. p-value = 0.082,  BPO Spearman Correlation  = -0.75,  Leukemia 
Spearman Correlation = 0.94), C) DLG4 and leucine (FDR adj. p-value = 0.0399,  BPO Spearman Correlation  = 0.78, Leukemia 
Spearman Correlation = -0.93)  
growth)	and	tumor	promoting	properties	(promotion	of	angiogenesis,	DNA	repair	mechanisms)	
[61].	 	 cAMP-regulator	 element	 binding	 protein	 (CREB)	 has	 been	 shown	 to	 be	 over-expressed	
and	phosphorylated	in	several	cancers	(including	acute	myeloid	leukemia)	and	might	play	a	role	
in	 cancer	 pathogenesis	 [62].	 These	 preliminary	 results	 demonstrate	 how	 different	 pathways	
may	be	differentially	regulated	in	a	cancer-type	dependent	manner.		Since	only	9	of	54	and	10	
of	 45	 metabolites	 in	 the	 leukemia	 correlated	 and	 leukemia	 anti-correlated	 clusters,	
respectively,	could	be	mapped	to	Human	Metabolome	Database	(HMDB)	IDs	[31-33],	pathway	
analyses	were	not	possible	for	the	metabolites.	
	
Application	to	Breast	Cancer	Data		
We	 further	 applied	 IntLIM	 to	 a	 previously	 published	 breast	 cancer	 study	 [9].	 	 Gene	
expression	 and	 metabolomics	 profiling	 of	 tumor	 (n	 =	 61)	 and	 adjacent	 non-tumor	 tissue	
samples	 (n	 =	 47)	was	measured	 in	 tissue	 from	breast	 cancer	patients	 [9].	 	 Importantly,	 gene	
expression	 and	metabolomics	were	measured	 in	 the	 same	 tissue	biospecimens.	 	 The	original	
study	 identified	 a	 relationship	 between	 MYC	 activation	 and	 2-hydroxyglutarate	 (2-HG)	
accumulation	 as	 associated	 with	 poor	 prognosis	 in	 breast	 cancer	 [9].	 Studies	 involving	MYC	
overexpression	and	knockdown	 in	human	mammary	epithelial	and	breast	cancer	cells	 further	
corroborated	 this	 relationship	 [9].	 When	 assessing	 the	 relationship	 between	 MYC	 gene	
expression	and	2-HG	though,	we	did	not	observe	this	association	at	the	transcription	level	(Fig.	
3C).	 Our	 goal	 was	 thus	 to	 identify	 other	 potential	 regulators	 of	 2-hydroxyglutarate	
accumulation	in	breast	cancer	tissue,	and	to	assess	whether	other	gene-metabolite	associations	
were	specific	to	either	tumor	or	non-tumor	tissue.		The	data	consists	of	18,228	genes	and	379	
metabolites	 (119	 unidentified)	 measured	 in	 61	 tumor	 samples	 and	 47	 adjacent	 non-tumor	
samples	 (Figure	 S2A	 and	 S2B).	 	 Unsupervised	 clustering	 of	 gene	 and	metabolite	 abundances	
separated	tumor	from	non-tumor	tissue	(Figure	S2C	and	S2D).			
	
IntLIM	 was	 applied	 to	 all	 possible	 combinations	 of	 gene-metabolite	 pairs	 (6,908,412	
models),	with	tumor	and	non-tumor	as	the	phenotype.		Our	approach	identified	2,842	tumor-
dependent	 gene-metabolite	 correlations	 (FDR-adjusted	 interaction	 p-value	 <	 0.05,	 and	 a	
Spearman	correlation	difference	>	0.5)	involving	761	genes	and	212	metabolites	of	which	48	are	
unidentified.	 (Data	 S2,	 Figure	 S3B).	 The	 resulting	 heatmap	 of	 gene-metabolite	 Spearman	
correlations	 for	 tumor	 and	 non-tumor	 groups	 is	 divided	 into	 two	major	 clusters	 (Figure	 3A).		
The	first	is	a	“tumor-correlated	cluster”	of	1,038	gene-metabolite	pairs		(288	unique	genes	and	
155	metabolites	of	which	35	are	unidentified)	with	relatively	high	correlations	in	tumor	samples	
and	mostly	negative	correlations	in	non-tumor	samples.		The	second	major	cluster,	“tumor	anti-
correlated	 cluster”,	 comprises	 1,804	 gene-metabolite	 pairs	 (479	 unique	 genes	 and	 188	
metabolites	 of	which	 39	 are	 unidentified)	with	 high	 negative	 correlations	 for	 tumor	 samples	
and	mostly	negative	correlations	for	non-tumor	samples.		
	
Upstream	analysis	of	 the	genes	 involved	 in	 the	 tumor-correlated	cluster	 (N	=	283)	did	
identify	MYC	as	an	upstream	transcriptional	regulator	(Right-tailed	Fisher’s	Exact	Test	p-value	=	
6x10-3),	 even	 though	MYC	 and	 2-HG	 are	 not	 differentially	 associated	 (Figure	 3C).	 2-HG	was,	
however,	found	to	be	associated	with	GPT2	(FDR	adj	p-value	=	0.046,	r	=	0.40	in	tumors,	and	r=-
0.11	 in	 non-tumors)	 (Figure	 3B,	 Data	 S2).	 GPT2	 plays	 a	 role	 in	 glutamine	 metabolism	 and	
encodes	 a	 glutamic-pyruvic	 transaminase	 that	 catalyzes	 reverse	 transamination	 between	
alanine	 and	 2-oxoglutarate	 to	 generate	 pyruvate	 and	 glutamate	 [63].	 	 Cancer	 cells	 exhibit	 a	
metabolic	 reprogramming	 that	 results	 in	 increased	 lactate	 acid	 production	 in	 the	 Warburg	
effect	and	the	use	of	glutamine	to	replenish	the	tricarboxylic	acid	cycle	(TCA)	[64,	65].		The	role	
of	GPT2	serves	to	drive	the	utilization	of	glutamine	as	a	carbon	source	for	TCA	analplerosis	[63,	
65].	While	 the	 exact	mechanisms	 underlying	 increased	 levels	 of	 2-hydroxyglutarate	 in	 breast	
cancer	cells	are	not	all	known,	our	results	suggest	that	metabolic	reprogramming	changes	the	
relationship	between	GPT2	and	2-hydroxyglutarate.	 	 Furthermore,	GPT2	 is	 found	 to	be	 in	 18	
(FDR	 adjusted	 p-value	 <	 0.05	 and	 correlation	 difference	 >	 0.5)	 other	 tumor-specific	 gene-
metabolite	associations	(Data	S2).				
	
In	 addition	 to	GPT2	 and	2-HG,	we	 identified	 15	other	 gene-metabolite	 pairs	 involving	
metabolites	 linked	 to	 glutamine	 metabolism.	 	 Of	 those	 genes	 paired	 with	 glutamine,	 ASNS,	
which	encodes	asparagine	 synthetase,	 is	directly	 involved	 in	metabolizing	glutamine	 [66]	and	
Figure 3.  Results of IntLIM applied to a breast cancer datase. A) Clustering of Spearman correlations of 2,842 identified gene-metabolite 
pairs(18,228 genes and 379 metabolites, with 61 tumor and 47 non-tumor samples) (FDR-adjusted p-value of interaction coefficient < 0.05 
with Spearman correlation difference of > 0.5) in tumor and non-tumor tissue from breast cancer tissue.  B) GPT2 association with 2-
hydroxyglutarate (FDR-adjusted p-value = 0.046,  Normal Spearman Correlation  = -0.11, Tumor Spearman Correlation = 0.40).  C) Lack of 
association between 2-hydroxygutarate with MYC (FDR adj. p-value = 0.90,  Normal Spearman Correlation  = -0.20, Tumor Spearman 
Correlation = 0.04) 
SLC7A1	 is	 involved	 in	 glutamine	 transport	 [64]	 (Data	 S2).	 	 Furthermore,	 there	 are	 65	 gene-
metabolite	pairs	with	glutamate	and	25	pairs	involving	alanine	(Data	S2),	and	5	gene-metabolite	
pairs	involving	the	WIF	gene,	which	is	part	of	the	Wnt	signaling	pathway	[9]	(Data	S2).			
	
Pathway	 analysis	 revealed	 that	 genes	 in	 the	 “tumor-correlated	 cluster”	 (283	mapped	
into	 IPA	 out	 of	 288	 genes)	 were	 enriched	 for	 oxidative	 phosphorylation,	 mitochondrial	
dysfunction,	protein	ubiquitination	pathway,	GDP-mannose	biosynthesis,	and	the	pyridoxal	5’-
phosphate	 salvage	 pathway	 (Table	 S2).	 	 Genes	 in	 the	 “tumor	 anti-correlated	 cluster”	 (468	
mapped	 onto	 IPA	 out	 of	 479	 genes)	 were	 enriched	 for	 hepatic	 fibrosis/hepatic	 stellate	 cell	
activation,	 FAK	 signaling,	 actin	 cytoskeleton	 signaling,	 signaling	 by	 Rho	 family	 GTPases,	 and	
circadian	rhythm	signaling	(Table	S2).		Expectedly,	we	find	that	pathways	such	as	FAK	signaling,	
actin	 cytoskeleton,	 the	 protein	 ubiquitination	 pathway,	 and	 circadian	 rhythm	 signaling	 have	
strong	 links	 to	 breast	 cancer	 pathogenesis	 [67-71].	 	 Of	 note,	 the	 top	 two	 pathways	 in	 the	
tumor-correlated	cluster	(oxidative	phosphorylation	and	mitochondrial	dysfunction)	play	roles	
in	cellular	energetics	[72].		
	
Pathway	 analysis	 of	 the	 metabolites	 in	 the	 “tumor-correlated	 cluster”	 (100	 mapped	
onto	IPA	out	of	155	metabolites)	resulted	in	enrichment	of	pathways	related	to	tRNA	charging	
and	nucleotide	degradation	(Table	S3).		The	“tumor	anti-correlated	cluster”	(115	mapped	onto	
IPA	out	of	188	metabolites)	was	also	enriched	 for	 tRNA	charging,	 citrulline	metabolism,	urea	
cycle,	 purine	 nucleotide	 degradation,	 and	 purine	 ribonucleosides	 degradation	 to	 ribose-1-
phosphate	 (Table	S3).	 	Pathways	 related	 to	 tRNA	and	 the	urea	cycle	have	been	 implicated	 in	
cancer	 [73-75].	 	Citrulline	metabolism	and	 the	urea	 cycle	have	also	been	 linked	 to	glutamine	
metabolism	[57,	76,	77].		These	findings	are	consistent	with	previous	studies	[9,	57,	63,	64]	that	
highlight	 the	 role	 of	 glutamine	 metabolism	 in	 cancer	 cell	 proliferation	 and	 maintenance,	
especially	 with	 regards	 to	 breast	 cancer[9].	 	 Further,	 the	 urea	 cycle	 has	 been	 shown	 to	 be	
implicated	 in	 breast	 cancer	 and	 is	 linked	 to	 glutamine	metabolism[77].	 	 Notably,	 our	 IntLIM	
results	 identify	 2	 gene-metabolite	 pairs	with	 urea	 and	 5	 gene-metabolite	 pairs	with	 arginine	
(FDR-adjusted	p-value	of	0.05	or	less,	absolute	Spearman	Correlation	difference	>	0.5),	a	major	
metabolite	in	the	urea	cycle	(S2	Data)	[77].	
	
Discussion	
	
As	 more	 and	 more	 transcriptomic	 and	 metabolomic	 data	 are	 collected	 in	 the	 same	
samples	or	 individuals,	 there	 is	 a	 need	 for	 streamlined	methods	 and	 associated	user-friendly	
tools	 that	 integrate	 these	 data.	We	 implemented	 a	 novel	 linear	 modeling	 approach	 into	 an	
IntLIM	R	package	that	includes	a	user-friendly	web	interface,	to	statistically	test	whether	gene	
and	 metabolite	 associations	 differ	 by	 phenotype.	 Formally	 testing	 this	 dependency	 on	
phenotype	 differentiates	 our	 approach	 from	other	 numerical	 integration	 approaches	 such	 as	
logistic	 regression	 and	 canonical	 correlations.	 Compared	 to	 other	 existing	methods	 that	 take	
into	account	phenotype	dependency	[20,	34],	 IntLIM	is	user-friendly,	 it	uses	a	well-developed	
methodology	(linear	model	interactions),	can	easily	account	for	other	covariables	(e.g.	gender,	
BMI,	 etc.),	 and	 can	 be	 applied	 to	 phenotypes	 that	 have	 more	 than	 two	 categories	 or	 are	
continuous.	 Ultimately,	 uncovering	 phenotype-specific	 relationships	 can	 provide	 insight	 into	
how	metabolites	are	being	regulated	by	genes	and	on	which	pathways	may	be	involved	in	these	
phenotype-specific	changes.		
	
While	 knowledge	 of	 relevant	 pathways	 is	 powerful	 in	 developing	 potential	 disease	
interventions	and	treatments,	pathway	enrichment	analyses	are	hampered	by	the	large	fraction	
of	 metabolites	 that	 are	 identified	 or	 cannot	 be	 mapped	 to	 pathways.	 	 Importantly,	 IntLIM	
uncovers	 phenotype-dependent	 gene-metabolite	 associations	 without	 a	 priori	 curated	
information	 on	 pathways	 and	 networks,	 allowing	 discovery	 of	 potentially	 novel	 associations	
(that	would	 require	 further	 experimental	 validation).	 Because	untargeted	metabolomics	 data	
produces	many	 unidentified	 features,	 phenotype-specific	 associations	with	 IntLIM	 could	 help	
further	characterize	these	unidentified	molecules.	These	data-driven	discoveries	would	require	
further	 experimental	 validation	 and	 could	 generate	 new	 hypothesis	 to	 be	 tested.	 When	
pathway	 annotations	 are	 available	 though,	 pathway	 enrichment	 analysis	 of	 genes	 and	
metabolites	that	show	similar	patterns	(e.g.	positive	correlation	in	tumors	but	no	correlation	in	
non-tumors)	 can	 offer	 greater	 insight	 onto	 pathways	 that	 are	 altered	 between	 phenotypes.	
With	this	in	mind,	IntLIM	produces	a	list	of	relevant	genes	and	metabolites	that	could	be	input	
into	pathway	integration	approaches	and	software	[26,	28-30].	
	
To	 demonstrate	 the	 utility	 of	 IntLIM	 to	 uncover	 cancer-relevant	 gene-metabolite	
relationships,	we	evaluated	transcriptomic	and	metabolomics	data	measured	in	the	NCI-60	cell	
lines	[10]	and	breast	tumor/adjacent	non-tumor	tissue	[9]	(Figures	2	and	3).		In	both	these	data	
sets,	 we	 uncovered	 biologically	 relevant	 gene-metabolite	 relationships	 and	 pathways.	 For	
example,	glutamine	metabolism	clearly	 stood	out	as	an	altered	pathway	 in	 the	breast	cancer	
data,	in	line	with	previous	published	results	[9].	Interestingly,	we	also	uncovered	novel	putative	
associations,	 such	as	 the	possible	modulation	by	GPT2	of	2-hydroxyglutarate	accumulation	 in	
breast	cancer	tissue	(validation	of	this	relationships	would	require	further	experimentation).			
	
While	 this	 first	 iteration	of	 IntLIM	uncovers	phenotype-specific	 gene-metabolite	pairs,	
the	approach	can	easily	be	extended	to	other	omics	data	(e.g.,	metabolomics/microbiome	data,	
metabolomics/proteome,	proteome/transcriptome).	 	Of	note,	because	 IntLIM	makes	use	of	a	
linear	model,	we	assume	that	 the	 independent	variables	 (e.g.	metabolite	 levels)	are	normally	
distributed	 to	meet	 the	normality	assumption.	We	have	verified	 the	normality	assumption	 in	
the	NCI-60	and	breast	cancer	datasets	and	 leave	 it	up	 to	 the	user	 to	appropriately	 transform	
and	 check	 the	normality	of	 their	 data	prior	 to	using	 IntLIM.	 	 Furthermore,	our	 current	 linear	
model	does	not	make	use	of	the	fact	that	some	of	the	samples	may	be	paired.	 	 In	our	breast	
cancer	data	[9],	only	a	subset	of	the	patients	(N	=	41)	have	both	tumor	and	adjacent	non-tumor	
available.		It	would	be	feasible	to	take	into	consideration	the	paired	nature	of	the	samples	using	
a	 mixed	 model	 methodology,	 and	 thereby	 increase	 our	 power	 to	 detect	 significant	
relationships.	 Finally,	 future	 developments	 of	 IntLIM	 will	 accommodate	 greater	 flexibility	 in	
defining	 models.	 For	 example,	 we	 will	 include	 the	 capability	 of	 testing	 whether	 phenotype-
specific	gene-metabolite	associations	are	independent	of	other	putative	confounders	(e.g.	age,	
gender,	 race,	 etc).	 	 Further,	 while	 IntLIM	 currently	 only	 supports	 a	 binary	 phenotype,	 it	 is	
readily	generalizable	to	multicategorical	phenotypes.					
	
Like	most	 approaches,	 IntLIM	 and	 the	 studies	 conducted	 are	 not	without	 limitations.		
The	 biochemical	 pathways	 that	 drive	 gene	 expression	 to	 protein	 production	 to	 post-
translational	 modifications	 to	 metabolite	 production/consumption	 are	 complex	 [24].	 The	
abundance	 of	 a	 given	 metabolite	 typically	 depend	 on	 a	 group	 of	 enzymes	 that	
produce/consume	 that	 metabolite.	 Additionally,	 those	 enzymes	 have	 distinct	 kinetic	
parameters,	 and	 their	 activity	 depends	 on	 a	 range	 of	 posttranslational	 modifications	 and	
regulatory	 processes.	 As	 a	 result,	 transcript	 levels	 are	 not	 the	 only	 factors	 that	 modulate	
metabolite	abundance,	and	the	gene-metabolite	relationship	may	not	be	linear.		In	this	regard,	
IntLIM	 may	 not	 adequately	 capture	 these	 complex	 relationships.	 Nonetheless,	 linear-based	
approaches	 are	well-developed,	 have	 successfully	 been	applied	when	 integrating	omics	data,	
and	co-regulated	genes	and	metabolites	tend	to	be	associated	with	functional	roles	[10,	20,	34].		
Further,	 we	 demonstrate	 that	 this	 simple	 approach	 can	 identify	 biologically	 meaningful,	
putative	 phenotype-dependent	 gene-metabolite	 relationships	 that	 can	 be	 investigated	 with	
further	experiments.	 	Another	 limitation	 is	 that	 IntLIM	does	not	take	 into	consideration	time-
dependency	 of	 biochemical	 reaction	 steps,	 especially	 given	 the	 time	 delay	 between	 gene	
expression	 and	 protein	 production	 and	 further	 on	 metabolite	 production/consumption.	
However,	 in	 clinical	 and	 translational	 applications,	 metabolomic	 and	 transcriptomic	 data	 is	
typically	 collected	 at	 a	 “snapshot”	 in	 time,	 where	 time-dependent	 analyses	 are	 not	 possible	
[78].	 Lastly,	 our	 approach,	 along	 with	 other	 numerical	 and	 pathway	 based	 integration	
approaches,	 does	 not	 take	 into	 account	 cellular	 heterogeneity	 in	 specimens	 analyzed,	 even	
though	 this	 heterogeneity	 could	 impact	 gene-metabolite	 correlations	 in	 different	 regions	 of	
cells	or	 tissues	 [79].	Because	 IntLIM	 remains	agnostic	 to	 the	 input,	especially	with	 regards	 to	
cell/tissue	heterogeneity,	 it	 is	 the	user’s	 responsibility	 to	 interpret	 the	data	as	well	 as	design	
future	experiments	 to	 test	 findings	 from	results.	 	Despite	 these	 limitations,	 IntLIM	provides	a	
user-friendly,	reproducible	framework	to	integrate	metabolomics	and	transcriptomics	data,	or	
other	omics	data	and	provides	a	readily	implementable	first	step	in	integration.			
	
Conclusions	
	
Metabolomics	and	transcriptomic	data	are	increasingly	collected	in	the	same	samples	to	
uncover	 putative	 metabolite	 biomarkers	 and	 gene	 therapeutic	 targets.	 	 User-friendly	
approaches	 that	 integrate	 these	 data	 types	 will	 thus	 facilitate	 data	 interpretation	 in	 these	
studies,	and	could	generate	data-driven	hypothesis.	With	 this	 in	mind,	we	developed	a	novel	
linear	 modeling	 approach	 that	 statistically	 tests	 whether	 gene-metabolite	 associations	 are	
specific	 to	 particular	 phenotypes	 (tumor	 vs.	 non-tumor,	 cancer-type,	 etc.).	 Our	 approach	 is	
available	 as	 a	 publicly	 available	 R	 package,	 IntLIM,	 with	 an	 associated	 user-friendly	 web	
application.	We	applied	IntLIM	to	two	cancer	datasets	and	uncovered	known	and	novel	gene-
metabolite	pairs	and	pathways	that	were	associated	with	cancer	phenotypes.	It	is	our	hope	that	
IntLIM	will	 assist	 researchers,	 with	 or	without	 computational	 expertise,	 in	 formulating	 novel	
hypothesis	 and	 proposing	 new	 studies	 especially	 with	 regards	 to	 the	 gene-metabolite	 pairs	
identified.		Integrating	the	results	with	pathway	analysis	tools	will	provide	further	insight.		The	
IntLIM	R	package	 and	App	 are	 available	 for	 download	 via	GitHub	 and	 a	 sample	 data-set	 and	
vignette	are	provided	for	users.			
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S1	Appendix	
	
IntLIM	Documentation	
	
Summary		
	
Interpretation	 of	 metabolomics	 data	 is	 very	 challenging.	 	 Yet	 it	 can	 be	 eased	 through	
integration	 of	 metabolmoics	 with	 other	 ‘omics’	 data.	 The	 IntLIM	 package,	 which	 includes	 a	
user-friendly	 RShiny	 web	 interface,	 aims	 to	 integrate	 metabolomic	 data	 with	 transcriptomic	
data.	 	We	 implement	 a	 simple	 linear	modeling	 approach	 to	 integration,	 where	we	 focus	 on	
understanding	how	specific	gene-metabolite	associations	are	affected	by	phenotypic	features.		
To	this	end,	we	include	an	interaction	term	in	our	linear	model	that	specifically	tests	whether	a	
gene-metabolite	association	differs	by	phenotype.		The	overall	workflow	involves	the	following	
steps:		
	
1)	input	gene	expression/metabolomics	data	files,		
2)	filter	data	sets	by	gene	and	metabolite	abundances	and	imputed	values,		
3)	 run	 linear	 models	 on	 all	 possible	 gene-metabolites	 pairs	 and	 extract	 FDR-adjusted	
interaction	p-values,		
4)	filter	results	by	FDR-adjusted	p-values	and	Spearman	correlation	differences,		
5)	plot/visualize	user-defined	gene-metabolite	associations		
	
The	package,	source	code,	vignettes,	and	formatted	datasets	used	in	to	produce	results	 in	
this	manuscript	are	available	for	download	on	GitHub	(https://github.com/mathelab/IntLIM).			
	
Installing	and	Running	IntLIM	
	
Installing	IntLIM	
	
The	“devtools”	package	(1)	is	the	simplest	way	to	directly	install	IntLIM:		
	
install.packages(devtools)	
library(devtools)	
install_github(“mathelab/IntLIM”)	
	
In	 some	 cases,	 it	 may	 be	 necessary	 to	 install	 the	 Bioconductor	 package	 MultiDataSet	
(Hernandez-Ferrer	et	al,	2017):	
	
	 ##	try	http://	if	https://	URLs	are	not	supported	
	 source("https://bioconductor.org/biocLite.R")	
	 biocLite("MultiDataSet")	
	
Running	IntLIM	
	
The	 IntLIM	package	provides	the	necessary	functions	to	carry	out	the	workflow	of	 integrating	
gene	 expression	 and	 metabolomics	 data	 and	 finding	 phenotype-dependent	 gene-metabolite	
associations.		The	information	below	is	meant	to	provide	an	overview	of	the	workflow	and	the	
functions	available	in	the	package.		Details	on	usage	and	parameters	available	for	each	function	
are	 included	 in	the	package	documentation	provided	by	each	function.	This	documentation	 is	
accessed	by	typing	“?functionname”,	where	“functionname”	is	the	name	of	the	function,	such	
as	ReadData,	FilterData,	etc.	
	
Step1:	Read	in	Data	
	
Through	 the	 ReadData()	 function,	 users	 input	 a	 comma-separated-values	 (CSV)	 file	 that	
contains	information	on	the	input	files.		This	input	CSV	file	must	contain	2	columns	and	6	rows	
and	must	include	the	following:	
	
			type,filenames		
			metabData,myfilename	
			geneData,myfilename	
			metabMetaData,myfilename	(optional)	
			geneMetaData,myfilename	(optional)	
			sampleMetaData,myfilename	
	
The	“myfilename”	represent	file	names	for	the	respective	data	types	without	the	file	directory,	
which	is	assumed	to	be	the	same	as	the	input	file.	Thus,	IntLIM	assumes	that	all	input	files	are	
in	 the	 same	 directory.	 	 The	 file	 names	 for	 the	 gene	 data	 (‘geneData’)	 and	metabolite	 data	
(‘metabData’)	must	be	normalized	and	can	be	optionally	transformed	(if	not	transformed,	the	
ReadData()	 has	 a	 parameter	 to	 apply	 log2	 transformation).	 Sample	 meta-data	
(‘sampleMetaData’)	must	include	at	least	one	phenotype	column	(to	calculate	the	linear	model	
interaction	 term).	 	Meta-data	 for	 genes	 and	metabolites	 (e.g.	 names,	 alternate	 ids,	 associate	
pathways)	are	optional.	The	gene	expression	data,	gene	meta-data,	and	sample	meta-data	are	
input	into	an	ExpressionSet	object.		The	metabolite	abundance	data,	metabolite	meta-data,	and	
sample	meta-data	are	 input	 into	a	new	MetaboliteSet	object,	 a	new	eSet	object	designed	 to	
contain	metabolomics	data	(2).		Both	objects	are	integrated	into	a	MultiDataSet	object-	a	multi-
‘omics	object	allowing	integration	of	eSet	objects	from	different	‘omics	data	sets.			
	
Step2:	Filter/Observe	Data	
	
The	FilterData()	 function	 filters	data	by	percentile	of	gene	expression/metabolite	abundances	
as	well	as	by	percent	of	missing	or	imputed	metabolite	values.			
	
The	ShowStats()	 function	summarizes	the	metabolite	and	gene	expression	data	by	number	of	
genes,	 metabolites,	 and	 samples	 for	 each	 set	 as	 well	 as	 common	 samples.	 	 The	
PlotDistribution()	 function	 allows	 users	 to	 produce	 a	 boxplot	 of	 the	 distribution	 of	 gene	
expression	and	metabolite	abundance	data	(Figure	1).		
		
Figure	4:		Example	distribution	of	genes	and	metabolites	
	
Prior	 to	 running	 the	model,	 the	user	 can	 also	perform	a	principal	 component	 analysis	 of	 the	
gene	 expression	 and	 metabolite	 data	 using	 the	 PlotPCA()	 function	 (Figure	 2).	 	 The	 ‘stype’	
command	allows	the	user	to	select	a	column	from	the	sample	meta	data	that	color-codes	the	
samples	into	two	categories	(two	cancer	types,	tumor	vs.	non-tumor,	etc).	
	
	
Figure	5:		Example	principal	component	analysis	plots	
	
Step3:	Run	IntLIM	
	
The	linear	models	are	run	by	the	RunIntLim()	function.		The	‘stype’	command	allows	the	user	to	
select	a	column	from	the	sample	meta	data	for	the	two	categories	to	be	compared	(two	cancer	
types,	 tumor	 vs.	 non-tumor,	 etc).	 	 Currently,	 IntLIM	 only	 supports	 comparison	 of	 two	
categories.	The	resulting	object	from	the	analysis	is	an	IntLimResults	object	containing	slots	for	
un-adjusted	and	False	Discovery	Rate	(FDR)-adjusted	p-values	for	the	interaction	coefficient.		A	
significant	 FDR-adjusted	p-value	 implies	 that	 the	 slope	of	 gene-metabolite	 association	 in	one	
phenotype	 is	 different	 from	 the	 other.	 	 The	 RunIntLim	 function	 is	 based	 heavily	 on	 the	
MultiLinearModel	 functions	 developed	 for	 the	 ClassComparison	 package	 part	 of	 oompa	
(http://oompa.r-forge.r-project.org).	 	 The	DistPValues()	 function	allows	 the	user	 to	observe	 a	
histogram	of	the	p-values	prior	to	adjustment	(Figure	3).		The	pvalCorrVolcano()	function	allows	
users	 to	 observe	 a	 volcano	 plot	 comparing	 the	 Spearman	 correlation	 difference	 between	
groups	to	the	–log10(FDR-adjusted	p-value)	(Figure	4).			
	
	
Figure	6:		Example	p-values	histogram	
	
Figure	7:		Example	volcano	plot	
	
	
Step4:		Filter	Results	
	
The	ProcessResults()	function	filters	the	results	by	FDR	p-values	(default	set	at	0.10)	and	by	the	
absolute	 value	 difference	 of	 the	 gene-metabolite	 Spearman	 correlation	 (default	 set	 at	 0.50)	
between	 the	 two	 groups.	 	 The	 output	 is	 a	 list	 of	 gene-metabolite	 pairs	 and	 gene-metabolite	
Spearman	correlations	for	each	of	the	two	groups.			
	
The	CorrHeatmap()	produces	a	clustered	heatmap	of	these	correlations	(Figure	5).			
	
Figure	8:		Example	gene-metabolite	correlation	heatmap	
	
Step5:		Visualize	and	Export	Results	
	
A	PlotGMPair()	function		produces	a	scatterplot	of	a	user-selected	gene-metabolite	pair,	which	
is	color-coded	by	phenotype	(Fig.	6)		
	
	 	
	
Figure	9:		Example	of	gene-metabolite	scatterplot	
	
Importantly,	most	plots	 generated	 in	 IntLIM	use	Highcharter	 (http://jkunst.com/highcharter/)	
and	 Plotly	 (3)	 (https://plot.ly),	 which	 enables	 interactive	 visualization	 and	 allows	 users	 to	
promptly	 assess	 the	 effect	 of	 changing	 parameters	 on	 analysis	 results	 and	 accelerating	
discovery	of	phenotype-specific	gene-metabolite	pairs.		This	will	greatly	allow	the	workflow	to	
be	accessible	to	non-computational	biologists.				
	
The	 OutputData()	 and	 OutputResults()	 function	 produces	 tables	 of	 data	 and	 results	 of	 the	
analyses	into	zipped	CSV	files.			
	
ShinyApp	User	Interface	
	
A	 Shiny	 App	 embedded	 in	 the	 package	 provides	 a	 user-friendly	 interface	 for	 running	 IntLIM	
(https://shiny.rstudio.com)	(Fig	7).	 	The	App	calls	functions	from	the	R	package	so	 includes	all	
the	 features	 describe	 above.	 	 These	 features	 include	 allowing	 users	 to	 input	 and	 observe	
distributions	 of	 transcriptomic	 and	metabolomic	 data	 (Figure	 7A),	 to	 filter	 input	 data	 (Figure	
7A),	 to	 produce	 distribution	 of	 adjusted	 p-values	 for	 interaction	 coefficients	 (Figure	 7B),	 to	
produce	 volcano	 plots	 of	 Spearman	 correlations/-log10(FDR-adjusted	 p-value)	 (Figure	 7B),	 to	
produce	 a	 heatmap	of	 gene-metabolite	 correlations	 for	 the	 two	 selected	 groups	 (Figure	 7C),	
and	to	produce	scatter-plots	of	select	gene-metabolite	pairs	(Figure	7D).		The	App	can	be	called	
by	typing	“runIntLIMApp()”	in	the	R	console	or	RStudio.			
	
	
Figure	10:		Example	of	Shiny	App.		A.	Inputting	and	filtering	data.	B.	Running	IntLIM	model	and	observing	p-value	distribution	
and	volcano	plots.	C.	Observing	heatmap	of	gene-metabolite	correlations.	D.	Scatterplots	of	select	gene-metabolite.		
	
	
	
	
Vignettes	
	
The	 IntLim	Github	repository	(https://github.com/mathelab/IntLIM)	 includes	a	vignette	with	a	
test	data	set,	which	includes	a	subset	of	gene	and	metabolite	levels	from	the	original	NCI-60	cell	
line	data(4).	This	reduced	dataset	allows	the	user	to	work	through	the	steps	of	the	workflow.		
For	the	data	analyzed	in	this	publication,	the	NCI-60	cell	 line	data	with	vignette	is	available	at	
https://github.com/Mathelab/NCI60_GeneMetabolite_Data,	 and	 the	 breast	 cancer	 data	 with	
vignette	 is	 available	 at	
https://github.com/Mathelab/BreastCancerAmbs_GeneMetabolite_Data.	
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Supplementary	Tables	
S1	Table:		NCI-60	Data	pathway	analysis	results	of	genes.	Ingenuity	Pathway	Analysis	Canonical	Pathways	from	
Genes	involved	in	Gene-Metabolite	Pairs	of	the	Leukemia	Correlated	Cluster	and	Leukemia	Anti-Correlated	Cluster.	
P-values	are	all	calculated	from	right-tailed	Fisher’s	Exact	Test.	
	
	
Leukemia	Correlated	Cluster	 Leukemia	Anti-Correlated	Cluster	
Pathway	 p-value	 Overlap	 Pathway	 p-value	 Overlap	
Acute	Phase	Response	
Signaling	 2.21E-04	
6.5%	
(11/170)	 eNOS	Signaling	 3.06E-04	
5.5%	
(10/181)	
1D-myo-inositol	
Hexakisphosphate	
Biosynthesis	V	(from	
Ins(1,3,4)P3)	
9.16E-04	 66.7%	(2/3)	 CREB	Signalling	in	Neurons	 5.08E-04	
5.2%	
(10/193)	
Hepatic	Fibrosis/Hepatic	
Stellate	Cell	Activation	 1.55E-04	
5.5%	
(10/183)	
dTMP	De	Novo	
Biosynthesis	 9.55E-04	
21.4%	
(3/14)	
CDK5	Signaling	 1.84E-04	 7.1%	(7/99)	 Huntington’s	Disease	Signaling	 1.02E-03	
4.4%	
(11/249)	
PAK	Signaling	 2.06E-04	 6.9%	(7/101)	
P2Y	Purigenic	Receptor	
Signaling	Pathway	 1.12E-03	
5.6%	
(8/143)	
	
S2	Table:		Breast	Cancer	Data	pathway	analysis	results	of	genes.	Ingenuity	Pathway	Analysis	Canonical	Pathways	
from	Genes	involved	in	Gene-Metabolite	Pairs	of	the	Tumor	Correlated	Cluster	and	Tumor	Anti-Correlated	Cluster.	
P-values	are	all	calculated	from	right-tailed	Fisher’s	Exact	Test.	
	
	
Tumor	Correlated	Cluster	 Tumor	Anti-Correlated	Cluster	
Name	 p-value	 Overlap	 Name	 p-value	 Overlap	
Oxidative	Phosphorylation	 2.00E-15	 16.5%	(18/109)	
Hepatic	
Fibrosis/Hepatic	
Stellate	Cell	
Activation	
1.21E-06	 8.7%	(16/183)	
Mitochondrial	Dysfunction	 4.98E-14	 11.7%	(20/171)	 FAK	Signaling	 3.56E-05	
10.1%	
(10/99)	
Protein	Ubiquitination	Pathway	 5.50E-04	 4.2%	(11/265)	
Actin	Cytoskeleton	
Signaling	 7.28E-05	
6.6%	
(15/227)	
GDP-mannose	Biosynthesis	 2.27E-03	 33.3%	(2/6)	
Signaling	by	Rho	
Family	GTPases	 1.94E-04	
6.0%	
(15/248)	
Pyridoxal	5'-phosphate	Salvage	
Pathway	 9.01E-03	
6.2%	
(4/65)	
Circadian	Rhythm	
Signaling	 5.18E-04	
15.2%	
(5/33)	
	
	
S3	Table:		Breast	Cancer	Data	pathway	analysis	results	of	metabolites.	Ingenuity	Pathway	Analysis	Canonical	
Pathways	from	Metabolites	involved	in	Gene-Metabolite	Pairs	of	the	Tumor	Correlated	Cluster.	P-values	are	all	
calculated	from	right-tailed	Fisher’s	Exact	Test.	
	
Tumor	Correlated	Cluster	 Tumor	Anti-Correlated	Cluster	
Name	 p-value	 Overlap	 Name	 p-value	 Overlap	
tRNA	charging	 1.33E-11	 39.5%	(17/43)	 tRNA	charging	 1.09E-11	
41.9%	
(18/43)	
Purine	Ribonucleosides	
Degradation	to	Ribose-1-
phosphate	
8.77E-07	 58.3%	(7/12)	
Superpathway	of	
Citrulline	
Metabolism	
6.83E-05	 33.3%	(8/24)	
Purine	Nucleotides	Degradation	II	
(Aerobic)	 1.71E-05	
41.2%	
(7/17)	 Urea	Cycle	 1.20E-04	
42.9%	
(6/14)	
Guanosine	Nucleotides	
Degradation	II	 1.01E-04	
50.0%	
(5/10)	
Purine	Nucleotides	
Degradation	II	
(Aerobic)	
4.22E-04	 35.3%	(6/17)	
Adenosine	Nucleotides	
Degradation	III	 1.78E-04	
45.5%	
(5/11)	
Purine	
Ribonucleosides	
Degradation	to	
Ribose-1-
phosphate	
5.50E-04	 41.7%	(5/12)	
	
	
	
	
